We have the unique capability to leverage multiple manufacturing facilities for our research and development and commercial manufacturing activities.
We have two in-house manufacturing facilities: a good manufacturing practice (GMP)-certified commercial manufacturing in Changxing, Zhejiang province, China, and a research and development and pilot manufacturing facility in Chengdu, Sichuan province, China. In addition, we have partnered with a contract development and manufacturing organization facility with European Union GMP certification to bolster our ability to flexibly supply our COVID-19 vaccine to meet demand in China and globally.
Our in-house, commercial-ready vaccines manufacturing facility in Changxing, Zhejiang province has achieved good manufacturing practice status for the production of SCB-2019 (CpG 1018/Alum) in China and is now supporting the commercial production of SCB-2019 (CpG 1018/Alum).
Located in Chengdu, Sichuan province, our R&D and pilot manufacturing facility supplies materials for our pre-clinical and early-stage clinical trials. It occupies approximately 3,300 square meters and contains a 200 liter single-use and 150 liter stainless steel bioreactor capacity as well as multiple pilot-scale drug product filling lines.